• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

IRAK4 Recombinant Monoclonal Antibody

The recombinant antibody against IRAK4 was produced using a synthesized peptide derived from human IRAK4 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, FC.

ADC-56942A

The recombinant antibody against IRAK4 was produced using a synthesized peptide derived from human IRAK4 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB, FC.

$350.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-56942A ClonalityMonoclonal
Target NameIRAK4Target SynonymsInterleukin-1 receptor-associated kinase 4 (IRAK-4) (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-64), IRAK4
FormLiquidSpecies ReactivityHuman
IsotypeRabbit IgGStorage BufferPH 7.4, 0.02% sodium azide and 50% glycerol., 150mM NaCl, Rabbit IgG in phosphate buffered saline
Purification MethodAffinity-chromatography purifiedConjugateNon-conjugated
ApplicationELISA, WB, FCStorageUpon receipt

Immunogen Information


Immunogen DescriptionA synthesized peptide derived from human IRAK4Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ9NWZ3
Background Information
  • Uniprot Id

    Q9NWZ3

  • Target Species

    Human

  • Target Name

    IRAK4

  • Target Full Name

    Interleukin-1 receptor-associated kinase 4

  • Target Function

    Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections.

  • Target Involvement

    Recurrent isolated invasive pneumococcal disease 1 (IPD1); IRAK4 deficiency (IRAK4D)

  • Target Subcellular Location

    Cytoplasm.

  • Target Protein Families

    Protein kinase superfamily, TKL Ser/Thr protein kinase family, Pelle subfamily

  • Target Synonyms

    IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; Interleukin-1 receptor-associated kinase 4; Interleukin1 receptor associated kinase 4; IPD1; IRAK 4; IRAK-4; IRAK4; IRAK4 mutated form 1; IRAK4_HUMAN; LOC 51135; NY REN 64; NY REN 64 antigen; NY-REN-64; REN64; Renal carcinoma antigen NY-REN-64

  • Target Background

    This gene encodes a kinase that activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. The protein is essential for most innate immune responses. Mutations in this gene result in IRAK4 deficiency and recurrent invasive pneumococcal disease. Multiple transcript variants encoding different isoforms have been found for this gene.

Inquire IRAK4 Recombinant Monoclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification